-
1
-
-
84867521031
-
Novel concepts in excitotoxic neurodegeneration after stroke
-
Aarts, M.M., Arundine, M., Tymianski, M., Novel concepts in excitotoxic neurodegeneration after stroke. Expert Rev. Mol. Med. 5 (2003), 1–22.
-
(2003)
Expert Rev. Mol. Med.
, vol.5
, pp. 1-22
-
-
Aarts, M.M.1
Arundine, M.2
Tymianski, M.3
-
2
-
-
83055178597
-
Novartis to shut brain research facility
-
Abbott, A., Novartis to shut brain research facility. Nature 480 (2011), 161–162.
-
(2011)
Nature
, vol.480
, pp. 161-162
-
-
Abbott, A.1
-
3
-
-
84865840573
-
Where will the (new) drugs for traumatic brain injury treatment be coming from?
-
Agoston, D.V., Risling, M., Where will the (new) drugs for traumatic brain injury treatment be coming from?. Front. Neurol., 3, 2012, 27.
-
(2012)
Front. Neurol.
, vol.3
, pp. 27
-
-
Agoston, D.V.1
Risling, M.2
-
4
-
-
55949117032
-
Frequent amyloid deposition without significant cognitive impairment among the elderly
-
Aizenstein, H.J., et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 65 (2008), 1509–1517.
-
(2008)
Arch. Neurol.
, vol.65
, pp. 1509-1517
-
-
Aizenstein, H.J.1
-
5
-
-
6944255523
-
Delivery of therapeutic agents to the central nervous system: the problems and the possibilities
-
Begley, D.J., Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 104 (2004), 29–45.
-
(2004)
Pharmacol. Ther.
, vol.104
, pp. 29-45
-
-
Begley, D.J.1
-
6
-
-
33947323759
-
Lost in translation: treatment trials in the SOD1 mouse and in human ALS
-
Benatar, M., Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol. Dis. 26 (2007), 1–13.
-
(2007)
Neurobiol. Dis.
, vol.26
, pp. 1-13
-
-
Benatar, M.1
-
7
-
-
84890136755
-
Successes and failures for drugs in late-stage development for Alzheimer's disease
-
Berk, C., Sabbagh, M.N., Successes and failures for drugs in late-stage development for Alzheimer's disease. Drugs Aging 30 (2013), 783–792.
-
(2013)
Drugs Aging
, vol.30
, pp. 783-792
-
-
Berk, C.1
Sabbagh, M.N.2
-
8
-
-
42749094007
-
Beyond NMDA and AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke
-
Besancon, E., et al. Beyond NMDA and AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke. Trends Pharmacol. Sci. 29 (2008), 268–275.
-
(2008)
Trends Pharmacol. Sci.
, vol.29
, pp. 268-275
-
-
Besancon, E.1
-
9
-
-
0033696608
-
Of mice and men (and women and children): scientific and ethical implications of animal models
-
Bird, S.J., Parlee, M.B., Of mice and men (and women and children): scientific and ethical implications of animal models. Prog. Neuropsychopharmacol. Biol. Psychiatry 24 (2000), 1219–1227.
-
(2000)
Prog. Neuropsychopharmacol. Biol. Psychiatry
, vol.24
, pp. 1219-1227
-
-
Bird, S.J.1
Parlee, M.B.2
-
10
-
-
70349119559
-
Rivastigmine for Alzheimer's Disease. Cochrane Database of Systematic Reviews
-
Birks, J.S., Chong, L.Y., Grimley, E.J., Rivastigmine for Alzheimer's Disease. Cochrane Database of Systematic Reviews. 2015.
-
(2015)
-
-
Birks, J.S.1
Chong, L.Y.2
Grimley, E.J.3
-
11
-
-
32944480791
-
Substance P (NK1) receptor antagonists—analgesics or not?
-
P. Holzer Springer Berlin Heidelberg
-
Boyce, S., Hill, R.G., Substance P (NK1) receptor antagonists—analgesics or not?. Holzer, P., (eds.) Tachykinins. Handbook of Experimental Pharmacology, vol. 164, 2004, Springer Berlin Heidelberg, 441–457.
-
(2004)
Tachykinins. Handbook of Experimental Pharmacology
, vol.164
, pp. 441-457
-
-
Boyce, S.1
Hill, R.G.2
-
12
-
-
0038745763
-
Animal models of mental retardation: from gene to cognitive function
-
Branchi, I., et al. Animal models of mental retardation: from gene to cognitive function. Neurosci. Biobehav Rev. 27 (2003), 141–153.
-
(2003)
Neurosci. Biobehav Rev.
, vol.27
, pp. 141-153
-
-
Branchi, I.1
-
13
-
-
84905823855
-
Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies
-
Broadstock, M., Ballard, C., Corbett, A., Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies. Expert Opin. Pharmacother. 15 (2014), 1797–1810.
-
(2014)
Expert Opin. Pharmacother.
, vol.15
, pp. 1797-1810
-
-
Broadstock, M.1
Ballard, C.2
Corbett, A.3
-
14
-
-
0030154620
-
Chemical chaperones correct the mutant phenotype of the delta-F508 cystic fibrosis transmembrane conductance regulator protein
-
Brown, C.R., et al. Chemical chaperones correct the mutant phenotype of the delta-F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1 (1996), 117–125.
-
(1996)
Cell Stress Chaperones
, vol.1
, pp. 117-125
-
-
Brown, C.R.1
-
15
-
-
77954145556
-
Fragile X mental retardation protein controls gating of the sodium-activated potassium channel slack
-
Brown, M.R., et al. Fragile X mental retardation protein controls gating of the sodium-activated potassium channel slack. Nat. Neurosci. 13 (2010), 819–821.
-
(2010)
Nat. Neurosci.
, vol.13
, pp. 819-821
-
-
Brown, M.R.1
-
16
-
-
80052784370
-
Potassium channel modulation and auditory processing
-
Brown, M.R., Kaczmarek, L.K., Potassium channel modulation and auditory processing. Hear Res. 279 (2011), 32–42.
-
(2011)
Hear Res.
, vol.279
, pp. 32-42
-
-
Brown, M.R.1
Kaczmarek, L.K.2
-
17
-
-
84863580562
-
Current and emerging therapies in multiple sclerosis: a systematic review
-
Castro-Borrero, W., et al. Current and emerging therapies in multiple sclerosis: a systematic review. Ther. Adv. Neurol. Disord. 5 (2012), 205–220.
-
(2012)
Ther. Adv. Neurol. Disord.
, vol.5
, pp. 205-220
-
-
Castro-Borrero, W.1
-
18
-
-
26844501218
-
Animal models of head trauma
-
Cernak, I., Animal models of head trauma. NeuroRx 2 (2005), 410–422.
-
(2005)
NeuroRx
, vol.2
, pp. 410-422
-
-
Cernak, I.1
-
19
-
-
0029060107
-
A change in gating mode leading to increased intrinsic Cl- channel activity compensates for defective processing in a cystic fibrosis mutant corresponding to a mild form of the disease
-
Champigny, G., et al. A change in gating mode leading to increased intrinsic Cl- channel activity compensates for defective processing in a cystic fibrosis mutant corresponding to a mild form of the disease. EMBO J. 14 (1995), 2417–2423.
-
(1995)
EMBO J.
, vol.14
, pp. 2417-2423
-
-
Champigny, G.1
-
20
-
-
0034776532
-
Patterns of cognitive decline in presymptomatic alzheimer disease: a prospective community study
-
Chen, P., et al. Patterns of cognitive decline in presymptomatic alzheimer disease: a prospective community study. Arch. Gen. Psychiatry 58 (2001), 853–858.
-
(2001)
Arch. Gen. Psychiatry
, vol.58
, pp. 853-858
-
-
Chen, P.1
-
21
-
-
0035049854
-
The maxi-K channel opener BMS-204352 attenuates regional cerebral edema and neurologic motor impairment after experimental brain injury
-
Cheney, J.A., et al. The maxi-K channel opener BMS-204352 attenuates regional cerebral edema and neurologic motor impairment after experimental brain injury. J. Cereb. Blood Flow Metab. 21 (2001), 396–403.
-
(2001)
J. Cereb. Blood Flow Metab.
, vol.21
, pp. 396-403
-
-
Cheney, J.A.1
-
22
-
-
19544376511
-
Neuroprotection for ischemic stroke: two decades of success and failure
-
Cheng, Y.D., Al-Khoury, L., Zivin, J.A., Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 1 (2004), 36–45.
-
(2004)
NeuroRx
, vol.1
, pp. 36-45
-
-
Cheng, Y.D.1
Al-Khoury, L.2
Zivin, J.A.3
-
23
-
-
45049084923
-
Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings
-
Conn, P.J., Roth, B.L., Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacology 33 (2008), 2048–2060.
-
(2008)
Neuropsychopharmacology
, vol.33
, pp. 2048-2060
-
-
Conn, P.J.1
Roth, B.L.2
-
24
-
-
79955511396
-
Translating promising preclinical neuroprotective therapies to human stroke trials
-
Cook, D.J., Tymianski, M., Translating promising preclinical neuroprotective therapies to human stroke trials. Expert Rev. Cardiovasc. Ther. 9 (2011), 433–449.
-
(2011)
Expert Rev. Cardiovasc. Ther.
, vol.9
, pp. 433-449
-
-
Cook, D.J.1
Tymianski, M.2
-
25
-
-
0034838257
-
Ischemic stroke: effects of etiology and patient age on the time course of the core apparent diffusion coefficient
-
Copen, W.A., et al. Ischemic stroke: effects of etiology and patient age on the time course of the core apparent diffusion coefficient. Radiology 221 (2001), 27–34.
-
(2001)
Radiology
, vol.221
, pp. 27-34
-
-
Copen, W.A.1
-
26
-
-
84860621838
-
The evolution of the cerebral blood volume abnormality in patients with ischemic stroke: a CT perfusion study
-
d'Esterre, C.D., Aviv, R.I., Lee, T.Y., The evolution of the cerebral blood volume abnormality in patients with ischemic stroke: a CT perfusion study. Acta Radiol. 53 (2012), 461–467.
-
(2012)
Acta Radiol.
, vol.53
, pp. 461-467
-
-
d'Esterre, C.D.1
Aviv, R.I.2
Lee, T.Y.3
-
27
-
-
0028933344
-
Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu, Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS)
-
Dal Canto, M.C., Gurney, M.E., Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu, Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res. 676 (1995), 25–40.
-
(1995)
Brain Res.
, vol.676
, pp. 25-40
-
-
Dal Canto, M.C.1
Gurney, M.E.2
-
28
-
-
68749100878
-
Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator
-
del Zoppo, G.J., et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator. Stroke 40 (2009), 2945–2948.
-
(2009)
Stroke
, vol.40
, pp. 2945-2948
-
-
del Zoppo, G.J.1
-
29
-
-
0026512066
-
Identification of normal and pathological aging in prospectively studied nondemented elderly humans
-
Dickson, D.W., et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol. Aging 13 (1992), 179–189.
-
(1992)
Neurobiol. Aging
, vol.13
, pp. 179-189
-
-
Dickson, D.W.1
-
30
-
-
38149033055
-
The 2007 Feinberg lecture: a new road map for neuroprotection
-
Donnan, G.A., The 2007 Feinberg lecture: a new road map for neuroprotection. Stroke 39 (2008), 242–248.
-
(2008)
Stroke
, vol.39
, pp. 242-248
-
-
Donnan, G.A.1
-
31
-
-
84866669849
-
Reviewing the role of Donepezil in the treatment of Alzheimer's disease
-
Doody, R.S., Cummings, J.L., Farlow, M.R., Reviewing the role of Donepezil in the treatment of Alzheimer's disease. Curr. Alzheimer Res. 9 (2012), 773–781.
-
(2012)
Curr. Alzheimer Res.
, vol.9
, pp. 773-781
-
-
Doody, R.S.1
Cummings, J.L.2
Farlow, M.R.3
-
32
-
-
0028126679
-
Cloning and expression of a human large-conductance calcium-activated potassium channel
-
Dworetzky, S.I., Trojnacki, J.T., Gribkoff, V.K., Cloning and expression of a human large-conductance calcium-activated potassium channel. Brain Res. Mol. Brain Res. 27 (1994), 189–193.
-
(1994)
Brain Res. Mol. Brain Res.
, vol.27
, pp. 189-193
-
-
Dworetzky, S.I.1
Trojnacki, J.T.2
Gribkoff, V.K.3
-
33
-
-
0031886652
-
Duration of neuroprotective treatment for ischemic stroke
-
Dyker, A.G., Lees, K.R., Duration of neuroprotective treatment for ischemic stroke. Stroke 29 (1998), 535–542.
-
(1998)
Stroke
, vol.29
, pp. 535-542
-
-
Dyker, A.G.1
Lees, K.R.2
-
34
-
-
84868243529
-
Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (Ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner
-
Eckford, P.D.W., et al. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (Ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J. Biol. Chem. 287 (2012), 36639–36649.
-
(2012)
J. Biol. Chem.
, vol.287
, pp. 36639-36649
-
-
Eckford, P.D.W.1
-
35
-
-
84948757442
-
Drug combinations in the treatment of neuropathic pain
-
Eisenberg, E., Suzan, E., Drug combinations in the treatment of neuropathic pain. Curr. Pain Headache Rep. 18 (2014), 1–8.
-
(2014)
Curr. Pain Headache Rep.
, vol.18
, pp. 1-8
-
-
Eisenberg, E.1
Suzan, E.2
-
36
-
-
84863669083
-
Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review
-
pii: e000917
-
Farrimond, L.E., Roberts, E., McShane, R., Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ Open, 2, 2012 pii: e000917.
-
(2012)
BMJ Open
, vol.2
-
-
Farrimond, L.E.1
Roberts, E.2
McShane, R.3
-
37
-
-
85020242278
-
The scientific agenda for AIDS
-
University of Texas at Dallas National Academy of Sciences
-
Fauci, A.S., The scientific agenda for AIDS. Issues in Science and Technology. VoSummer, 2003, 2003, University of Texas at Dallas, National Academy of Sciences.
-
(2003)
Issues in Science and Technology. VoSummer, 2003
-
-
Fauci, A.S.1
-
38
-
-
0043013350
-
Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case fatality in the late 20th century
-
Feigin, V.L., Lawes, C.M., Bennett, D.A., Anderson, C.S., Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case fatality in the late 20th century. Lancet Neurol. 2 (2003), 43–53.
-
(2003)
Lancet Neurol.
, vol.2
, pp. 43-53
-
-
Feigin, V.L.1
Lawes, C.M.2
Bennett, D.A.3
Anderson, C.S.4
-
39
-
-
62949129784
-
Translational medicine for stroke drug discovery: the pharmaceutical industry perspective
-
Feuerstein, G.Z., Chavez, J., Translational medicine for stroke drug discovery: the pharmaceutical industry perspective. Stroke 40 (2009), S121–S125.
-
(2009)
Stroke
, vol.40
, pp. S121-S125
-
-
Feuerstein, G.Z.1
Chavez, J.2
-
40
-
-
0032748815
-
Neuroprotection of acute ischemic stroke: where are we?
-
Fisher, M., Neuroprotection of acute ischemic stroke: where are we?. Neurosci. 5 (1999), 392–401.
-
(1999)
Neurosci.
, vol.5
, pp. 392-401
-
-
Fisher, M.1
-
41
-
-
0037975646
-
Recommendations for advancing development of acute stroke therapies: stroke therapy academic industry roundtable 3
-
Fisher, M., Stroke Therapy Academic Industry, R, Recommendations for advancing development of acute stroke therapies: stroke therapy academic industry roundtable 3. Stroke 34 (2003), 1539–1546.
-
(2003)
Stroke
, vol.34
, pp. 1539-1546
-
-
Fisher, M.1
Stroke Therapy Academic Industry, R,2
-
42
-
-
66849097996
-
Update of the stroke therapy academic industry roundtable preclinical recommendations
-
Fisher, M., et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40 (2009), 2244–2250.
-
(2009)
Stroke
, vol.40
, pp. 2244-2250
-
-
Fisher, M.1
-
43
-
-
84867530358
-
Identifying and utilizing the ischemic penumbra
-
Fisher, M., Bastan, B., Identifying and utilizing the ischemic penumbra. Neurology 79 (2012), S79–S85.
-
(2012)
Neurology
, vol.79
, pp. S79-S85
-
-
Fisher, M.1
Bastan, B.2
-
44
-
-
0030451306
-
Presymptomatic hippocampal atrophy in Alzheimer's disease
-
Fox, N.C., et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. Brain 119 (1996), 2001–2007.
-
(1996)
Brain
, vol.119
, pp. 2001-2007
-
-
Fox, N.C.1
-
45
-
-
0028985574
-
Alzheimer-type neuropathology in transgenic mice overexpressing V717F [beta]-amyloid precursor protein
-
Games, D., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F [beta]-amyloid precursor protein. Nature 373 (1995), 523–527.
-
(1995)
Nature
, vol.373
, pp. 523-527
-
-
Games, D.1
-
46
-
-
0021894801
-
Animal behavioral models in the discovery of compounds to treat memory dysfunction
-
Gamzu, E., Animal behavioral models in the discovery of compounds to treat memory dysfunction. Ann. N. Y. Acad. Sci. 444 (1985), 370–393.
-
(1985)
Ann. N. Y. Acad. Sci.
, vol.444
, pp. 370-393
-
-
Gamzu, E.1
-
47
-
-
84873487586
-
Genentech's Alzheimer's antibody trial to study disease prevention
-
Garber, K., Genentech's Alzheimer's antibody trial to study disease prevention. Nat. Biotech. 30 (2012), 731–732.
-
(2012)
Nat. Biotech.
, vol.30
, pp. 731-732
-
-
Garber, K.1
-
48
-
-
0036330007
-
Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions
-
Gladstone, D.J., et al. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33 (2002), 2123–2136.
-
(2002)
Stroke
, vol.33
, pp. 2123-2136
-
-
Gladstone, D.J.1
-
49
-
-
3142655729
-
Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy
-
Gotz, J., et al. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol. Psychiatry 9 (2004), 664–683.
-
(2004)
Mol. Psychiatry
, vol.9
, pp. 664-683
-
-
Gotz, J.1
-
50
-
-
84930677623
-
Does long term use of psychiatric drugs cause more harm than good?
-
Gøtzsche, P.C., Young, A.H., Crace, J., Does long term use of psychiatric drugs cause more harm than good?. BMJ, 350, 2015, h2435.
-
(2015)
BMJ
, vol.350
, pp. h2435
-
-
Gøtzsche, P.C.1
Young, A.H.2
Crace, J.3
-
51
-
-
84947917035
-
Memantine ER/Donepezil: a review in Alzheimer's disease
-
Springer International Publishing
-
Greig, S., Memantine ER/Donepezil: a review in Alzheimer's disease. CNS Drugs, 2015, Springer International Publishing, 1–8.
-
(2015)
CNS Drugs
, pp. 1-8
-
-
Greig, S.1
-
52
-
-
0028247368
-
The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel
-
Gribkoff, V.K., et al. The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel. J. Biol. Chem. 269 (1994), 10983–10986.
-
(1994)
J. Biol. Chem.
, vol.269
, pp. 10983-10986
-
-
Gribkoff, V.K.1
-
53
-
-
9344266364
-
Effects of channel modulators on cloned large-conductance calcium-activated potassium channels
-
Gribkoff, V.K., et al. Effects of channel modulators on cloned large-conductance calcium-activated potassium channels. Mol. Pharmacol. 50 (1996), 206–217.
-
(1996)
Mol. Pharmacol.
, vol.50
, pp. 206-217
-
-
Gribkoff, V.K.1
-
54
-
-
0035052573
-
Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels
-
Gribkoff, V.K., et al. Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat. Med. 7 (2001), 471–477.
-
(2001)
Nat. Med.
, vol.7
, pp. 471-477
-
-
Gribkoff, V.K.1
-
55
-
-
43349097329
-
The therapeutic potential of neuronal K V 7 (KCNQ) channel modulators: an update
-
Gribkoff, V.K., The therapeutic potential of neuronal K V 7 (KCNQ) channel modulators: an update. Expert Opin. Ther. Targets 12 (2008), 565–581.
-
(2008)
Expert Opin. Ther. Targets
, vol.12
, pp. 565-581
-
-
Gribkoff, V.K.1
-
56
-
-
84919625840
-
Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: from review to preview
-
Grupke, S., et al. Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: from review to preview. Clin. Neurol. Neurosurg. 129 (2015), 1–9.
-
(2015)
Clin. Neurol. Neurosurg.
, vol.129
, pp. 1-9
-
-
Grupke, S.1
-
57
-
-
84857769209
-
Multiple sclerosis - remyelination failure as a cause of disease progression
-
Hagemeier, K., Bruck, W., Kuhlmann, T., Multiple sclerosis - remyelination failure as a cause of disease progression. Histol. Histopathol. 27 (2012), 277–287.
-
(2012)
Histol. Histopathol.
, vol.27
, pp. 277-287
-
-
Hagemeier, K.1
Bruck, W.2
Kuhlmann, T.3
-
58
-
-
85020245050
-
-
L.M. Hardy Institute of Medicine, The National Academies of Sciences, Engineering and Medicine
-
Hardy, L.M., Hardy, L.M., (eds.) Government and industry collaboration in AIDS drug development, 1994, Institute of Medicine, The National Academies of Sciences, Engineering and Medicine, 1–18.
-
(1994)
Government and industry collaboration in AIDS drug development
, pp. 1-18
-
-
Hardy, L.M.1
-
59
-
-
84868632227
-
Why is publication of negative clinical trial data important?
-
Hayes, A., Hunter, J., Why is publication of negative clinical trial data important?. Br. J. Pharmacol. 167 (2012), 1395–1397.
-
(2012)
Br. J. Pharmacol.
, vol.167
, pp. 1395-1397
-
-
Hayes, A.1
Hunter, J.2
-
60
-
-
34250731169
-
Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies
-
Hazell, A.S., Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies. Neurochem. Int. 50 (2007), 941–953.
-
(2007)
Neurochem. Int.
, vol.50
, pp. 941-953
-
-
Hazell, A.S.1
-
61
-
-
79961220833
-
Disease modification in Parkinson's disease
-
Henchcliffe, C., Severt, W.L., Disease modification in Parkinson's disease. Drugs Aging 28 (2011), 605–615.
-
(2011)
Drugs Aging
, vol.28
, pp. 605-615
-
-
Henchcliffe, C.1
Severt, W.L.2
-
62
-
-
33750579981
-
Multiple sclerosis: new insights and trends
-
Inglese, M., Multiple sclerosis: new insights and trends. Am. J. Neuroradiol. 27 (2006), 954–957.
-
(2006)
Am. J. Neuroradiol.
, vol.27
, pp. 954-957
-
-
Inglese, M.1
-
63
-
-
0032174282
-
Formation of intermediate-conductance calcium-activated potassium channels by interaction of slack and slo subunits
-
Joiner, W.J., et al. Formation of intermediate-conductance calcium-activated potassium channels by interaction of slack and slo subunits. Nat. Neurosci. 1 (1998), 462–469.
-
(1998)
Nat. Neurosci.
, vol.1
, pp. 462-469
-
-
Joiner, W.J.1
-
64
-
-
84977933014
-
Half of US clinical trials go unpublished
-
Dec 3, 2013
-
Jones, N., Half of US clinical trials go unpublished. Nat. News, 2013 Dec 3, 2013.
-
(2013)
Nat. News
-
-
Jones, N.1
-
65
-
-
33748943301
-
Non-conducting functions of voltage-gated ion channels
-
Kaczmarek, L.K., Non-conducting functions of voltage-gated ion channels. Nat. Rev. Neurosci. 7 (2006), 761–771.
-
(2006)
Nat. Rev. Neurosci.
, vol.7
, pp. 761-771
-
-
Kaczmarek, L.K.1
-
66
-
-
84904400166
-
Slack, slick and sodium-activated potassium channels
-
pii: 354262
-
Kaczmarek, L.K., Slack, slick and sodium-activated potassium channels. ISRN Neurosci., 2013, 2013 pii: 354262.
-
(2013)
ISRN Neurosci.
, vol.2013
-
-
Kaczmarek, L.K.1
-
67
-
-
84940983037
-
Modeling psychiatric disorders for developing effective treatments
-
Kaiser, T., Feng, G., Modeling psychiatric disorders for developing effective treatments. Nat. Med. 21 (2015), 979–988.
-
(2015)
Nat. Med.
, vol.21
, pp. 979-988
-
-
Kaiser, T.1
Feng, G.2
-
68
-
-
84940598230
-
CNS drugs take longer to develop, have lower success rates, than other drugs
-
K.I. Kaitin Tufts University, Tufts Center for the Study of Drug Development
-
Kaitlin, K.I., CNS drugs take longer to develop, have lower success rates, than other drugs. Kaitin, K.I., (eds.) Tufts CSDD Impact Reports, vol. 16, 2014, Tufts University, Tufts Center for the Study of Drug Development, 1–4.
-
(2014)
Tufts CSDD Impact Reports
, vol.16
, pp. 1-4
-
-
Kaitlin, K.I.1
-
69
-
-
0023851810
-
Autoimmunity in multiple sclerosis
-
371–371
-
Keyser, J.D., Autoimmunity in multiple sclerosis. Neurology, 38, 1988 371–371.
-
(1988)
Neurology
, vol.38
-
-
Keyser, J.D.1
-
70
-
-
0034983276
-
Trends in acute ischemic stroke trials through the 20th century
-
Kidwell, C.S., et al. Trends in acute ischemic stroke trials through the 20th century. Stroke 32 (2001), 1349–1359.
-
(2001)
Stroke
, vol.32
, pp. 1349-1359
-
-
Kidwell, C.S.1
-
71
-
-
0033542395
-
Effects of tissue plasminogen activator for acute ischemic stroke at one year
-
Kwiatkowski, T.G., et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N. Engl. J. Med. 340 (1999), 1781–1787.
-
(1999)
N. Engl. J. Med.
, vol.340
, pp. 1781-1787
-
-
Kwiatkowski, T.G.1
-
72
-
-
0035213050
-
Animal models of nociception
-
le Bars, D., Gozariu, M., Cadden, S.W., Animal models of nociception. Pharmacol. Rev. 53 (2001), 597–652.
-
(2001)
Pharmacol. Rev.
, vol.53
, pp. 597-652
-
-
le Bars, D.1
Gozariu, M.2
Cadden, S.W.3
-
73
-
-
0036105484
-
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis
-
Lock, C., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8 (2002), 500–508.
-
(2002)
Nat. Med.
, vol.8
, pp. 500-508
-
-
Lock, C.1
-
74
-
-
84929292051
-
Time course and predictors of neurological deterioration after intracerebral hemorrhage
-
Lord, A.S., et al. Time course and predictors of neurological deterioration after intracerebral hemorrhage. Stroke 46 (2015), 647–652.
-
(2015)
Stroke
, vol.46
, pp. 647-652
-
-
Lord, A.S.1
-
75
-
-
0242610016
-
Topography and temporal resolution of hypoxic viable tissue identified by 18F-fluoromisonidazole positron emission tomography in humans after ischemic stroke
-
Markus, R., et al. Topography and temporal resolution of hypoxic viable tissue identified by 18F-fluoromisonidazole positron emission tomography in humans after ischemic stroke. Stroke 34 (2003), 2646–2652.
-
(2003)
Stroke
, vol.34
, pp. 2646-2652
-
-
Markus, R.1
-
76
-
-
84892371678
-
Animal models of CNS disorders
-
McGonigle, P., Animal models of CNS disorders. Biochem. Pharmacol. 87 (2014), 140–149.
-
(2014)
Biochem. Pharmacol.
, vol.87
, pp. 140-149
-
-
McGonigle, P.1
-
77
-
-
85020317969
-
New drug combination could extend life of cystic fibrosis patients
-
May 2015
-
McIntosh, J., New drug combination could extend life of cystic fibrosis patients. Medical News Today, vol. 18, 2015 May 2015.
-
(2015)
Medical News Today
, vol.18
-
-
McIntosh, J.1
-
78
-
-
77955114844
-
Is pharma running out of brainy ideas?
-
Miller, G., Is pharma running out of brainy ideas?. Science 329 (2010), 502–504.
-
(2010)
Science
, vol.329
, pp. 502-504
-
-
Miller, G.1
-
79
-
-
84861941975
-
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
-
Miller, R.G., Mitchell, J.D., Moore, D.H., Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev., 2012, 10.1002/14651858.CD001447.pub3.
-
(2012)
Cochrane Database Syst. Rev.
-
-
Miller, R.G.1
Mitchell, J.D.2
Moore, D.H.3
-
80
-
-
84884550190
-
Current and future therapies for multiple sclerosis
-
Minagar, A., Current and future therapies for multiple sclerosis. Scientifica 2013 (2013), 1–11.
-
(2013)
Scientifica
, vol.2013
, pp. 1-11
-
-
Minagar, A.1
-
81
-
-
0141836222
-
Excitatory amino acid antagonists for acute stroke
-
Muir, K.W., Lees, K.R., Excitatory amino acid antagonists for acute stroke. Cochrane Database Syst. Rev., 2003, 10.1002/14651858.CD001244.
-
(2003)
Cochrane Database Syst. Rev.
-
-
Muir, K.W.1
Lees, K.R.2
-
82
-
-
77957273984
-
Animal models of neuropsychiatric disorders
-
Nestler, E.J., Hyman, S.E., Animal models of neuropsychiatric disorders. Nat. Neurosci. 13 (2010), 1161–1169.
-
(2010)
Nat. Neurosci.
, vol.13
, pp. 1161-1169
-
-
Nestler, E.J.1
Hyman, S.E.2
-
83
-
-
84888199614
-
Imaging of cerebral ischemia: from acute stroke to chronic disorders
-
Nour, M., Liebeskind, D.S., Imaging of cerebral ischemia: from acute stroke to chronic disorders. Neurol. Clin. 32 (2014), 1–24.
-
(2014)
Neurol. Clin.
, vol.32
, pp. 1-24
-
-
Nour, M.1
Liebeskind, D.S.2
-
84
-
-
0038039305
-
Animal models of depression: are there any?
-
O'Neil, M.F., Moore, N.A., Animal models of depression: are there any?. Hum. Psychopharmacol. 18 (2003), 239–254.
-
(2003)
Hum. Psychopharmacol.
, vol.18
, pp. 239-254
-
-
O'Neil, M.F.1
Moore, N.A.2
-
85
-
-
33750924816
-
The blood-brain barrier and epilepsy
-
Oby, E., Janigro, D., The blood-brain barrier and epilepsy. Epilepsia 47 (2006), 1761–1774.
-
(2006)
Epilepsia
, vol.47
, pp. 1761-1774
-
-
Oby, E.1
Janigro, D.2
-
86
-
-
84863536950
-
N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease
-
Olivares, D., et al. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. Curr. Alzheimer's Res., 9, 2012, 13.
-
(2012)
Curr. Alzheimer's Res.
, vol.9
, pp. 13
-
-
Olivares, D.1
-
87
-
-
84907054900
-
Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
-
Panza, F., et al. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?. Expert Opin. Biol. Ther. 14 (2014), 1465–1476.
-
(2014)
Expert Opin. Biol. Ther.
, vol.14
, pp. 1465-1476
-
-
Panza, F.1
-
88
-
-
84890992887
-
The roles of K+ channels in cancer
-
Pardo, L.A., Stuhmer, W., The roles of K+ channels in cancer. Nat. Rev. Cancer 14 (2014), 39–48.
-
(2014)
Nat. Rev. Cancer
, vol.14
, pp. 39-48
-
-
Pardo, L.A.1
Stuhmer, W.2
-
89
-
-
84868573143
-
Drug transport across the blood-brain barrier
-
Pardridge, W.M., Drug transport across the blood-brain barrier. J. Cereb. Blood Flow Metab. 32 (2012), 1959–1972.
-
(2012)
J. Cereb. Blood Flow Metab.
, vol.32
, pp. 1959-1972
-
-
Pardridge, W.M.1
-
90
-
-
42649137566
-
Traumatic brain injury: can the consequences be stopped?
-
Park, E., Bell, J.D., Baker, A.J., Traumatic brain injury: can the consequences be stopped?. Can. Med. Assoc. J. 178 (2008), 1163–1170.
-
(2008)
Can. Med. Assoc. J.
, vol.178
, pp. 1163-1170
-
-
Park, E.1
Bell, J.D.2
Baker, A.J.3
-
91
-
-
84923331513
-
Building a roadmap for developing combination therapies for Alzheimer's disease
-
Perry, D., et al. Building a roadmap for developing combination therapies for Alzheimer's disease. Expert Rev. Neurother. 15 (2015), 327–333.
-
(2015)
Expert Rev. Neurother.
, vol.15
, pp. 327-333
-
-
Perry, D.1
-
92
-
-
0033662408
-
Transgenic animals as models for human disease
-
Petters, R.M., Sommer, J.R., Transgenic animals as models for human disease. Transgenic Res. 9 (2000), 347–351.
-
(2000)
Transgenic Res.
, vol.9
, pp. 347-351
-
-
Petters, R.M.1
Sommer, J.R.2
-
93
-
-
60549107281
-
Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials
-
Philip, M., et al. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke 40 (2009), 577–581.
-
(2009)
Stroke
, vol.40
, pp. 577-581
-
-
Philip, M.1
-
94
-
-
84930179409
-
Memantine extended release (28 mg once daily): a review of its use in Alzheimer's disease
-
Plosker, G., Memantine extended release (28 mg once daily): a review of its use in Alzheimer's disease. Drugs 75 (2015), 887–897.
-
(2015)
Drugs
, vol.75
, pp. 887-897
-
-
Plosker, G.1
-
95
-
-
85020310194
-
Orkambi, a new cystic fibrosis drug, wins F.D.A. approval
-
Pollack, A., Orkambi, a new cystic fibrosis drug, wins F.D.A. approval. The New York Times. July 2, 2015, 2015.
-
(2015)
The New York Times. July 2, 2015
-
-
Pollack, A.1
-
96
-
-
0027289075
-
The evolution of acute stroke recorded by multimodal magnetic resonance imaging
-
Quast, M.J., et al. The evolution of acute stroke recorded by multimodal magnetic resonance imaging. Magn. Reson Imaging 11 (1993), 465–471.
-
(1993)
Magn. Reson Imaging
, vol.11
, pp. 465-471
-
-
Quast, M.J.1
-
97
-
-
33645675839
-
Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease
-
Radad, K., Gille, G., Rausch, W.-D., Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol. Rep. 57 (2005), 701–712.
-
(2005)
Pharmacol. Rep.
, vol.57
, pp. 701-712
-
-
Radad, K.1
Gille, G.2
Rausch, W.-D.3
-
98
-
-
0024424270
-
Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA
-
Riordan, J.R., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245 (1989), 1066–1073.
-
(1989)
Science
, vol.245
, pp. 1066-1073
-
-
Riordan, J.R.1
-
99
-
-
0027481813
-
The cystic-fibrosis transmembrane conductance regulator
-
Riordan, J.R., The cystic-fibrosis transmembrane conductance regulator. Ann. Rev. Physiol. 55 (1993), 609–630.
-
(1993)
Ann. Rev. Physiol.
, vol.55
, pp. 609-630
-
-
Riordan, J.R.1
-
100
-
-
84877578442
-
Changing patterns in the epidemiology of traumatic brain injury
-
Roozenbeek, B., Maas, A.I.R., Menon, D.K., Changing patterns in the epidemiology of traumatic brain injury. Nat. Rev. Neurol. 9 (2013), 231–236.
-
(2013)
Nat. Rev. Neurol.
, vol.9
, pp. 231-236
-
-
Roozenbeek, B.1
Maas, A.I.R.2
Menon, D.K.3
-
101
-
-
85020308815
-
Mouse Models of Alzheimer's Disease: What Are They Modeling? 2015 Neuroscience Meeting Abstracts Online
-
Rose, G.M., Hayashi, E., Patrylo, P.R., Mouse Models of Alzheimer's Disease: What Are They Modeling? 2015 Neuroscience Meeting Abstracts Online. 2015.
-
(2015)
-
-
Rose, G.M.1
Hayashi, E.2
Patrylo, P.R.3
-
102
-
-
84879000844
-
Cystic fibrosis transmembrane regulator correctors and potentiators
-
pii: a009761
-
Rowe, S.M., Verkman, A.S., Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb. Perspect. Med., 3, 2013 pii: a009761.
-
(2013)
Cold Spring Harb. Perspect. Med.
, vol.3
-
-
Rowe, S.M.1
Verkman, A.S.2
-
103
-
-
84892695519
-
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease
-
Salloway, S., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370 (2014), 322–333.
-
(2014)
N. Engl. J. Med.
, vol.370
, pp. 322-333
-
-
Salloway, S.1
-
104
-
-
84941117181
-
Recent advances in the pharmacological management of acute and chronic pain
-
Schug, S.A., Goddard, C., Recent advances in the pharmacological management of acute and chronic pain. Ann. Palliat. Med. 3 (2014), 263–275.
-
(2014)
Ann. Palliat. Med.
, vol.3
, pp. 263-275
-
-
Schug, S.A.1
Goddard, C.2
-
105
-
-
39349107014
-
Design, power, and interpretation of studies in the standard murine model of ALS
-
Scott, S., et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph. Lateral Scler. 9 (2008), 4–15.
-
(2008)
Amyotroph. Lateral Scler.
, vol.9
, pp. 4-15
-
-
Scott, S.1
-
106
-
-
26844449402
-
Transgenic models of Alzheimer's disease: learning from animals
-
Spires, T.L., Hyman, B.T., Transgenic models of Alzheimer's disease: learning from animals. NeuroRx 2 (2005), 423–437.
-
(2005)
NeuroRx
, vol.2
, pp. 423-437
-
-
Spires, T.L.1
Hyman, B.T.2
-
107
-
-
79953093064
-
Drugs and clinical trials in neurodegenerative diseases
-
Stanzione, P., Tropepi, D., Drugs and clinical trials in neurodegenerative diseases. Ann. Ist. Super. Sanita 47 (2011), 49–54.
-
(2011)
Ann. Ist. Super. Sanita
, vol.47
, pp. 49-54
-
-
Stanzione, P.1
Tropepi, D.2
-
108
-
-
84924939833
-
Chapter 28-Recent developments in clinical trials for the treatment of traumatic brain injury
-
G. Jordan M.S. Andres Elsevier
-
Stein, D.G., Geddes, R.I., Sribnick, E.A., Chapter 28-Recent developments in clinical trials for the treatment of traumatic brain injury. Jordan, G., Andres, M.S., (eds.) Handbook of Clinical Neurology, vol. 127, 2015, Elsevier, 433–451.
-
(2015)
Handbook of Clinical Neurology
, vol.127
, pp. 433-451
-
-
Stein, D.G.1
Geddes, R.I.2
Sribnick, E.A.3
-
109
-
-
77955393170
-
Fragile X mental retardation protein is required for rapid experience-dependent regulation of the potassium channel Kv3.1b
-
Strumbos, J.G., et al. Fragile X mental retardation protein is required for rapid experience-dependent regulation of the potassium channel Kv3.1b. J. Neurosci. 30 (2010), 10263–10271.
-
(2010)
J. Neurosci.
, vol.30
, pp. 10263-10271
-
-
Strumbos, J.G.1
-
110
-
-
84878190712
-
Future viable models of psychiatry drug discovery in pharma
-
Sukoff Rizzo, S.J., et al. Future viable models of psychiatry drug discovery in pharma. J. Biomol. Screen. 18 (2013), 509–521.
-
(2013)
J. Biomol. Screen.
, vol.18
, pp. 509-521
-
-
Sukoff Rizzo, S.J.1
-
111
-
-
33846459373
-
Animal models relevant to schizophrenia and autism: validity and limitations
-
Tordjman, S., et al. Animal models relevant to schizophrenia and autism: validity and limitations. Behav. Genet. 37 (2007), 61–78.
-
(2007)
Behav. Genet.
, vol.37
, pp. 61-78
-
-
Tordjman, S.1
-
112
-
-
67651095785
-
Dosing of anti-psychotics in schizophrenia across the life spectrum
-
Uchida, H., Mamo, D.C., Dosing of anti-psychotics in schizophrenia across the life spectrum. Prog. Neuropsychopharmacol. Biol. Psychiatry 33 (2009), 917–920.
-
(2009)
Prog. Neuropsychopharmacol. Biol. Psychiatry
, vol.33
, pp. 917-920
-
-
Uchida, H.1
Mamo, D.C.2
-
113
-
-
80051544073
-
Animal models in the drug discovery pipeline for Alzheimer's disease
-
Van Dam, D., De Deyn, P.P., Animal models in the drug discovery pipeline for Alzheimer's disease. Br. J. Pharmacol. 164 (2011), 1285–1300.
-
(2011)
Br. J. Pharmacol.
, vol.164
, pp. 1285-1300
-
-
Van Dam, D.1
De Deyn, P.P.2
-
114
-
-
65349125962
-
Evaluation of animal models of neurobehavioral disorders
-
van der Staay, F.J., Arndt, S.S., Nordquist, R.E., Evaluation of animal models of neurobehavioral disorders. Behav. Brain Funct. 5 (2009), 1–23.
-
(2009)
Behav. Brain Funct.
, vol.5
, pp. 1-23
-
-
van der Staay, F.J.1
Arndt, S.S.2
Nordquist, R.E.3
-
115
-
-
84882308754
-
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force
-
Vellas, B., et al. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 9 (2013), 438–444.
-
(2013)
Alzheimers Dement.
, vol.9
, pp. 438-444
-
-
Vellas, B.1
-
116
-
-
0030981003
-
Riluzole: a new agent for amyotrophic lateral sclerosis
-
Wagner, M.L., Landis, B.E., Riluzole: a new agent for amyotrophic lateral sclerosis. Ann. Pharmacother. 31 (1997), 738–744.
-
(1997)
Ann. Pharmacother.
, vol.31
, pp. 738-744
-
-
Wagner, M.L.1
Landis, B.E.2
-
117
-
-
0033809127
-
Screening of antipsychotic drugs in animal models
-
Weiner, I., et al. Screening of antipsychotic drugs in animal models. Drug Dev. Res. 50 (2000), 235–249.
-
(2000)
Drug Dev. Res.
, vol.50
, pp. 235-249
-
-
Weiner, I.1
-
118
-
-
34447527791
-
Pathophysiology of traumatic brain injury
-
Werner, C., Engelhard, K., Pathophysiology of traumatic brain injury. Br. J. Anaesth. 99 (2007), 4–9.
-
(2007)
Br. J. Anaesth.
, vol.99
, pp. 4-9
-
-
Werner, C.1
Engelhard, K.2
-
119
-
-
0021348560
-
The validity of animal models of depression
-
Willner, P., The validity of animal models of depression. Psychopharmacol. Berl. 83 (1984), 1–16.
-
(1984)
Psychopharmacol. Berl.
, vol.83
, pp. 1-16
-
-
Willner, P.1
-
120
-
-
0023000704
-
Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case
-
Willner, P., Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case. Prog. Neuropsychopharmacol. Biol. Psychiatry 10 (1986), 677–690.
-
(1986)
Prog. Neuropsychopharmacol. Biol. Psychiatry
, vol.10
, pp. 677-690
-
-
Willner, P.1
-
121
-
-
0003083366
-
Behavioural models in psychopharmacology
-
P. Willner Cambridge University Press Cambridge
-
Willner, P., Behavioural models in psychopharmacology. Willner, P., (eds.) Behavioural Models in Psychopharmacology Theoretical, Industrial and Clinical Perspectives, 1991, Cambridge University Press, Cambridge, 3–18.
-
(1991)
Behavioural Models in Psychopharmacology Theoretical, Industrial and Clinical Perspectives
, pp. 3-18
-
-
Willner, P.1
-
122
-
-
84896734453
-
We can treat Alzheimer's disease successfully in mice but not in men: failure in translation? A perspective
-
Windisch, M., We can treat Alzheimer's disease successfully in mice but not in men: failure in translation? A perspective. Neurodegener. Dis. 13 (2014), 147–150.
-
(2014)
Neurodegener. Dis.
, vol.13
, pp. 147-150
-
-
Windisch, M.1
-
123
-
-
33747836278
-
Pharmacological activation and inhibition of slack (slo2.2) channels
-
Yang, B., et al. Pharmacological activation and inhibition of slack (slo2.2) channels. Neuropharmacology 51 (2006), 896–906.
-
(2006)
Neuropharmacology
, vol.51
, pp. 896-906
-
-
Yang, B.1
-
124
-
-
35448967751
-
Neuroprotection and stroke: time for a compromise
-
Young, A.R., et al. Neuroprotection and stroke: time for a compromise. J. Neurochem. 103 (2007), 1302–1309.
-
(2007)
J. Neurochem.
, vol.103
, pp. 1302-1309
-
-
Young, A.R.1
-
125
-
-
84982206792
-
Kv3.3 potassium channels and spinocerebellar ataxia
-
Oct. 7
-
Zhang, Y., Kaczmarek, L.K., Kv3.3 potassium channels and spinocerebellar ataxia. J. Physiol., 2015, 10.1113/JP271343 Oct. 7.
-
(2015)
J. Physiol.
-
-
Zhang, Y.1
Kaczmarek, L.K.2
|